Louisiana State Employees Retirement System Makes New $3.09 Million Investment in Illumina, Inc. (NASDAQ:ILMN)

Louisiana State Employees Retirement System purchased a new position in Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,200 shares of the life sciences company’s stock, valued at approximately $3,091,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ILMN. Acadian Asset Management LLC boosted its stake in Illumina by 312.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock worth $702,000 after purchasing an additional 1,525 shares during the period. Dimensional Fund Advisors LP boosted its stake in Illumina by 3.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock worth $82,853,000 after purchasing an additional 7,114 shares during the period. Dakota Wealth Management boosted its stake in Illumina by 13.8% in the 1st quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock worth $288,000 after purchasing an additional 100 shares during the period. Sequoia Financial Advisors LLC boosted its position in shares of Illumina by 16.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock valued at $281,000 after acquiring an additional 116 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its position in shares of Illumina by 10.2% during the 1st quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock valued at $17,108,000 after acquiring an additional 4,548 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. OTR Global reiterated a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Stephens reiterated an “overweight” rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, April 10th. Scotiabank upgraded Illumina from a “sector perform” rating to a “sector outperform” rating and set a $185.00 target price for the company in a research report on Monday, December 18th. Royal Bank of Canada reiterated an “outperform” rating and set a $253.00 target price on shares of Illumina in a research report on Tuesday, April 9th. Finally, TD Cowen downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price for the company. in a research report on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average price target of $167.70.

Illumina Trading Down 4.7 %

ILMN stock opened at $121.16 on Tuesday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. The business’s fifty day simple moving average is $135.35 and its two-hundred day simple moving average is $128.35. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $232.23.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business’s revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.14 earnings per share. As a group, analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current year.

Insider Activity

In other news, CEO Jacob Thaysen purchased 7,330 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the purchase, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.17% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.